Moreover, changes in the proliferative epidermal growth factor receptor (EGFR) pathway influence the response to androgen deprivation therapy (in advanced cases of the prostate cancer) and can modulate cancer progression in different cancer models (Wang et al., 2007; Teixeira et al., 2009; Costa et al., 2011). This evidence concerns the gene EGFR and Familial prostate cancer.